Anti-SSA/Ro autoantibodies

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Health, Clinical trials, Other Health, Medical specialties, Branches of biology, Clinical medicine, Immunology, Antibodies, Chemical pathology, Communication, Forward-looking statement, Anti-SSA/Ro autoantibodies, Vaccine

Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.

Key Points: 
  • Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
  • The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
  • Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.
  • Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.

AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions

Retrieved on: 
Tuesday, July 13, 2021
Autoimmune diseases, Medical specialties, Clinical medicine, Cutaneous lupus erythematosus, Medicine, Lupus, William Osler, Connective tissue diseases, Anti-SSA/Ro autoantibodies

This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.

Key Points: 
  • This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.
  • Assessment of the confidence in the diagnosis of SLE and initiation of hydroxychloroquine (HCQ) showed that the AVISE Lupus test impacted physician behavior.
  • In particular, physician certainty in an SLE diagnosis increased with increasing AVISE Lupus scores.
  • Similarly, certainty in an SLE diagnosis decreased when an AVISE Lupus score was negative, indicating that the test helped in both ruling-in and in ruling-out the disease.

SLE-UPDATE Study Finds Reducing Pain, Fatigue, and Flares are Top Treatment Goals for People with Lupus

Retrieved on: 
Monday, June 28, 2021
Medical specialties, Autoimmune diseases, Clinical medicine, Cutaneous lupus erythematosus, Medicine, Lupus, William Osler, Anti-SSA/Ro autoantibodies, Neonatal lupus erythematosus, Lupus Canada

The study, "Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey," was conducted by the Lupus Foundation of America and Eli Lilly and Company, and highlights the importance of patient reported symptoms and treatment goals to improve quality of life.

Key Points: 
  • The study, "Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey," was conducted by the Lupus Foundation of America and Eli Lilly and Company, and highlights the importance of patient reported symptoms and treatment goals to improve quality of life.
  • The SLE-UPDATE study is a follow-up study to the Lupus Foundation of America and Eli Lilly and Company UNVEIL survey from 2014 which examined the burden of SLE for patients and caregivers in the US.
  • "The voice of people with lupus is incredibly important when understanding treatment needs.
  • Read the full study here and check out an infographic highlighting findings from the study.

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

Retrieved on: 
Thursday, June 17, 2021
Medical specialties, Autoimmune diseases, Branches of biology, Clinical medicine, Cutaneous lupus erythematosus, Monoclonal antibodies, Antibodies, Lupus, William Osler, Anti-SSA/Ro autoantibodies, Immunoglobulin E, Tolerx

Based on the positive results observed in the Phase 2 LILAC study, we are excited to continue to evaluate the potential of BIIB059 in TOPAZ-1.

Key Points: 
  • Based on the positive results observed in the Phase 2 LILAC study, we are excited to continue to evaluate the potential of BIIB059 in TOPAZ-1.
  • TOPAZ-1 is a 52-week, multicenter, randomized double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of BIIB059 compared with placebo.
  • The initiation of the TOPAZ-1 study is based on the results from the Phase 2 LILAC study.
  • BIIB059, discovered and developed exclusively by Biogen, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

$4.7 Billion Autoimmune Diseases Diagnostics Global Market to 2026 - Technological Innovation in the Form of Lab Automation Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Science, Health, Other Science, Other Health, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Rheumatology, Immunology, Connective tissue diseases, Autoimmunity, Arthritis, Autoimmune disease, Type 1 diabetes, Anti-SSA/Ro autoantibodies

The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • An autoimmune disease is a disorder wherein one's immune system attacks the body and destroys its body tissue.
  • There have been around 80 different types of autoimmune disorders being identified, of which, multiple sclerosis, type 1 diabetes, rheumatoid arthritis are fairly common.
  • Factors such as a rise in the incidence of autoimmune diseases have been a major driver for the growth of the market of autoimmune drugs.

Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Kidney diseases, Connective tissue diseases, Antibodies, Autoantibodies, Lupus, Nephritis, Anti-SSA/Ro autoantibodies, Sjögren syndrome

A live webcast of the presentation can be accessed by visiting the investor relations section of the Companys website, www.veratx.com.

Key Points: 
  • A live webcast of the presentation can be accessed by visiting the investor relations section of the Companys website, www.veratx.com.
  • A replay of the webcast will also be available and archived on the site for 90 days following the presentation date.
  • Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases.
  • In addition, Vera is evaluating additional diseases where atacicepts reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE).

Sentinel Diagnostics Launches Two New Serological Tests To Quickly Assess The Immunoresponse To SARS-CoV-2

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Branches of biology, Medicine, Autoantibodies, Chemical pathology, Antibody, Glycoproteins, Immunology, COVID-19, Anti-SSA/Ro autoantibodies

"We have developed our new quick solution that supports the continuous monitoring of epidemic to ensure public health decisions delivering fast results.

Key Points: 
  • "We have developed our new quick solution that supports the continuous monitoring of epidemic to ensure public health decisions delivering fast results.
  • The first kit detects the total antibodies against the Spike RBD S1 protein, while the second detects the antibodies against Nucleocapsid (NC) protein.\nThe new Sentinel Diagnostics assays provide the first results in about 10 minutes.
  • The use of Sentinel COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab would help distinguish vaccinated individuals from naturally infected ones.
  • The tests can be performed together on the same serum sample or separately to better fit with laboratory needs.\n'

Sentinel Diagnostics Launches Two New Serological Tests To Quickly Assess The Immunoresponse To SARS-CoV-2

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Branches of biology, Medicine, Immunologic tests, COVID-19, Occupational safety and health, Public health, Zoonoses, Serology, Serum, Anti-SSA/Ro autoantibodies

"We have developed our new quick solution that supports the continuous monitoring of epidemic to ensure public health decisions delivering fast results.

Key Points: 
  • "We have developed our new quick solution that supports the continuous monitoring of epidemic to ensure public health decisions delivering fast results.
  • The first kit detects the total antibodies against the Spike RBD S1 protein, while the second detects the antibodies against Nucleocapsid (NC) protein.\nThe new Sentinel Diagnostics assays provide the first results in about 10 minutes.
  • The use of Sentinel COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab would help distinguish vaccinated individuals from naturally infected ones.
  • The tests can be performed together on the same serum sample or separately to better fit with laboratory needs.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/sentinel-diagnostics-launches-tw...\n'

Exagen Announces New Campaign and Initiatives for Lupus Awareness Month

Retrieved on: 
Monday, May 3, 2021
Medical specialties, Autoimmune diseases, Clinical medicine, Medicine, Connective tissue diseases, Cutaneous lupus erythematosus, Syndromes, Lupus, William Osler, Sjögren syndrome, Anti-SSA/Ro autoantibodies, Autoimmunity

b'SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.\xc2\xa0(Nasdaq: XGN),\xc2\xa0a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely diagnosis and patient monitoring for Systemic Lupus Erythematosus (SLE).\nEmphasizing the patient journey from overlapping symptoms to diagnosis and monitoring, Exagen has launched a new campaign called \xe2\x80\x9cKnow With AVISE\xe2\x80\x9d.

Key Points: 
  • b'SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.\xc2\xa0(Nasdaq: XGN),\xc2\xa0a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely diagnosis and patient monitoring for Systemic Lupus Erythematosus (SLE).\nEmphasizing the patient journey from overlapping symptoms to diagnosis and monitoring, Exagen has launched a new campaign called \xe2\x80\x9cKnow With AVISE\xe2\x80\x9d.
  • Each week in the month of May, Exagen will focus on a step in the patient\xe2\x80\x99s journey with lupus to bring attention to the signs and symptoms of lupus and the issues and challenges people face.
  • In collaboration with the Lupus Foundation of America, Exagen will shed light on the difficulties of diagnosing lupus accurately, as well as racial and health disparities many face throughout their journey.
  • Exagen\xe2\x80\x99s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021

Retrieved on: 
Tuesday, April 27, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Autoantibodies, Arthritis, XC2, Anti-SSA/Ro autoantibodies, Rheumatoid arthritis, Sjögren syndrome

b'SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.\xc2\xa0(Nasdaq: XGN),\xc2\xa0a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021.

Key Points: 
  • b'SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.\xc2\xa0(Nasdaq: XGN),\xc2\xa0a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021.
  • Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13718936.
  • Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE\xc2\xae brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology.
  • Exagen\xe2\x80\x99s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.